Bone microenvironment modulates expression and activity of cathepsin B in prostate cancer

Neoplasia

Volumn 7, Issue 3, 2005, Pages 207-223

  Podgorski, Izabela ^a   Linebaugh, Bruce E ^a   Sameni, Mansoureh ^a   Jedeszko, Christopher ^a   Bhagat, Sunita ^a   Cher, Michael L ^a,b   Sloane, Bonnie F ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

Author keywords

Bone microenvironment; Cathepsin B; Osteolysis; Prostate cancer; Tumor stromal interactions

Indexed keywords

CATHEPSIN B; COLLAGEN; COLLAGEN TYPE 4; CYSTEINE PROTEINASE; FIBROBLAST GROWTH FACTOR; MATRIX METALLOPROTEINASE INHIBITOR; MATRIX PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE; UROKINASE;

ARTICLE; BASEMENT MEMBRANE; BONE METASTASIS; BONE TISSUE; CELL INTERACTION; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; MICROENVIRONMENT; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; STROMA CELL; TUMOR CELL CULTURE; TUMOR GROWTH;

EID: 15744371624     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1593/neo.04349     Document Type: Article

References (100)

1. Buck MR, Karustis DG, Day NA, Honn KV, and Sloane BF (1992). Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues. Biochem J 282, 273-278.
2. Johnsen M, Lund LR, Romer J, Almholt K, and Dano K (1998). Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation. Curr Opin Cell Biol 10, 667-671.
3. Garcia M, Platet N, Liaudet E, Laurent V, Derocq D, Brouillet JP, and Rochefort H (1996). Biological and clinical significance of cathepsin D in breast cancer metastasis. Stem Cells 14, 642-650.
4. Khan A, Krishna M, Baker SP, Malhothra R, and Banner BF (1998). Cathepsin B expression and its correlation with tumor-associated laminin and tumor progression in gastric cancer. Arch Pathol Lab Med 122, 172-177.
5. Zeng ZS, Cohen AM, and Guillem JG (1999). Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumorigenesis. Carcinogenesis 20, 749-755.
6. Yoneda T (1998). Cellular and molecular mechanisms of breast and prostate cancer metastasis to bone. Eur J Cancer 34, 240-245.
7. Klein CE, Dressel D, Steinmayer T, Mauch C, Eckes B, Krieg T, Bankert RB, and Weber L (1991). Integrin alpha 2 beta 1 is upregulated in fibroblasts and highly aggressive melanoma cells in three-dimensional collagen lattices and mediates the reorganization of collagen I fibrils. J Cell Biol 115, 1427-1436.
8. Kostenuik PJ, Sanchez-Sweatman O, Orr FW, and Singh G (1996). Bone cell matrix promotes the adhesion of human prostatic carcinoma cells via the alpha 2 beta 1 integrin. Clin Exp Metastasis 14, 19-26.
9. Stanton H, Gavrilovic J, Atkinson SJ, d'Ortho MP, Yamada KM, Zardi L, and Murphy G (1998). The activation of ProMMP-2 (gelatinase A) by HT1080 fibrosarcoma cells is promoted by culture on a fibronectin substrate and is concomitant with an increase in processing of MT1-MMP (MMP-14) to a 45 kDa form. J Cell Sci 111, 2789-2798.
10. Mauch C, Adelmann-Grill B, Hatamochi A, and Krieg T (1989). Collagenase gene expression in fibroblasts is regulated by a three-dimensional contact with collagen. FEBS Lett 250, 301-305.
11. Khan KM and Falcone DJ (1997). Role of laminin in matrix induction of macrophage urokinase-type plasminogen activator and 92-kDa metalloproteinase expression. J Biol Chem 272, 8270-8275.
12. Koblinski JE, Dosescu J, Sameni M, Moin K, Clark K, and Sloane BF (2002). Interaction of human breast fibroblasts with collagen I increases secretion of procathepsin B. J Biol Chem 277, 32220-32227.
13. Sinha AA, Gleason DF, Deleon OF, Wilson MJ, and Sloane BF (1993). Localization of a biotinylated cathepsin B oligonucleotide probe in human prostate including invasive cells and invasive edges by in situ hybridization. Anat Rec 235, 233-240.
14. Sinha AA, Wilson MJ, Gleason DF, Reddy PK, Sameni M, and Sloane BF (1995). Immunohistochemical localization of cathepsin B in neoplastic human prostate. Prostate 26, 171-178.
15. McGowen R, Biliran H Jr, Sager R, and Sheng S (2000). The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin. Cancer Res 60, 4771-4778.
16. Kobayashi H, Moniwa N, Sugimura M, Shinohara H, Ohi H, and Terao T (1993). Increased cell-surface urokinase in advanced ovarian cancer. Jpn J Cancer Res 84, 633-640.
17. Guo M, Mathieu PA, Linebaugh B, Sloane BF, and Reiners JJ Jr (2002). Phorbol ester activation of a proteolytic cascade capable of activating latent transforming growth factor-betaL a process initiated by the exocytosis of cathepsin B. J Biol Chem 277, 14829-14837.
18. Murphy G, Ward R, Gavrilovic J, and Atkinson S (1992). Physiological mechanisms for metalloproteinase activation. Matrix Suppl 1, 224-230.
19. Kostoulas G, Lang A, Nagase H, and Baici A (1999). Stimulation of angiogenesis through cathepsin B inactivation of the tissue inhibitors of matrix metalloproteinases. FEBS Lett 455, 286-290.
20. Nemeth JA, Harb JF, Barroso U Jr, He Z, Grignon DJ, and Cher ML (1999). Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone. Cancer Res 59, 1987-1993.
21. Moin K, Day NA, Sameni M, Hasnain S, Hirama T, and Sloane BF (1992). Human tumour cathepsin B. Comparison with normal liver cathepsin B. Biochem J 285, 427-434.
22. Stone KR, Mickey DD, Wunderli H, Mickey GH, and Paulson DF (1978). Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 21, 274-281.
23. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, and Jones LW (1979). Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 17, 16-23.
24. Horoszewicz JS, Leong SS, Chu TM, Wajsman ZL, Friedman M, Papsidero L, Kim U, Chai LS, Kakati S, Arya SK, and Sandberg AA (1980). The LNCaP cell line-a new model for studies on human prostatic carcinoma. Prog Clin Biol Res 37, 115-132.
25. Sameni M, Moin K, and Sloane BF (2000). Imaging proteolysis by living human breast cancer cells. Neoplasia 2, 496-504.
26. Sameni M, Dosescu J, and Sloane BF (2001). Imaging proteolysis by living human glioma cells. Biol Chem 382, 785-788.
27. Sameni M, Dosescu J, Moin K, and Sloane BF (2003). Functional imaging of proteolysis: stromal and inflammatory cells increase tumor proteolysis. Mol Imaging 2, 159-175.
28. Murata M, Miyashita S, Yokoo C, Tamai M, Hanada K, Hatayama K, Towatari T, Nikawa T, and Katunuma N (1991). Novel epoxysuccinyl peptides. Selective inhibitors of cathepsin B, in vitro. FEBS Lett 280, 307-310.
29. Yamamoto A, Hara T, Tomoo K, Ishida T, Fujii T, Hata Y, Murata M, and Kitamura K (1997). Binding mode of CA074, a specific irreversible inhibitor, to bovine cathepsin B as determined by X-ray crystal analysis of the complex. J Biochem (Tokyo) 121, 974-977.
30. Montaser M, Lalmanach G, and Mach L (2002). CA-074, but not its methyl ester CA-074Me, is a selective inhibitor of cathepsin B within living cells. Biol Chem 383, 1305-1308.
31. Downs TR and Wilfinger WW (1983). Fluorometric quantification of DNA in cells and tissue. Anal Biochem 131, 538-547.
32. Linebaugh BE, Sameni M, Day NA, Sloane BF, and Keppler D (1999). Exocytosis of active cathepsin B enzyme activity at pH 7.0, inhibition and molecular mass. Eur J Biochem 264, 100-109.
33. Hulkower KI, Butler CC, Linebaugh BE, Klaus JL, Keppler D, Giranda VL, and Sloane BF (2000). Fluorescent microplate assay for cancer cell-associated cathepsin B. Eur J Biochem 267, 4165-4170.
34. Barrett AJ, Kembhavi AA, Brown MA, Kirschke H, Knight CG, Tamai M, and Hanada K (1982). L-trans-epoxysuccinyl-leucylamido(4-guanidino)-butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L. Biochem J 201, 189-198.
35. Galardy RE, Grobelny D, Foellmer HG, and Fernandez LA (1994). Inhibition of angiogenesis by the matrix metalloprotease inhibitor N-[2R-2- (hydroxamidocarbonymethyl)-4-methylpentanoyl)]-L-tryptophan methylamide. Cancer Res 54, 4715-4718.
36. Gebhard W, Tschesche H, and Fritz H (1986). Biochemistry of aprotinin and aprotinin-like inhibitors, Proteinase Inhibitors pp.375-388 Elsevier Science, New York.
37. Roshy S, Sloane BF, and Moin K (2003). Pericellular cathepsin B and malignant progression. Cancer Metastasis Rev 22, 271-286.
38. Sloane BF, Moin K, Sameni M, Tait LR, Rozhin J, and Ziegler G (1994). Membrane association of cathepsin B can be induced by transfection of human breast epithelial cells with c-Ha-ras oncogene. J Cell Sci 107, 373-384.
39. Sameni M, Elliott E, Ziegler G, Fortgens PH, Dennison C, and Sloane BF (1995). Cathepsin B and D are localized at the surface of human breast cancer cells. Pathol Oncol Res 1, 43-53.
40. Campo E, Munoz J, Miquel R, Palacin A, Cardesa A, Sloane BF, and Emmert-Buck MR (1994). Cathepsin B expression in colorectal carcinomas correlates with tumor progression and shortened patient survival. Am J Pathol 145, 301-309.
41. Rempel SA, Rosenblum ML, Mikkelsen T, Yan PS, Ellis KD, Golembieski WA, Sameni M, Rozhin J, Ziegler G, and Sloane BF (1994). Cathepsin B expression and localization in glioma progression and invasion. Cancer Res 54, 6027-6031.
42. Everts V, Delaisse JM, Korper W, and Beertsen W (1998). Cysteine proteinases and matrix metalloproteinases play distinct roles in the subosteoclastic resorption zone. J Bone Miner Res 13, 1420-1430.
43. Hill PA, Buttle DJ, Jones SJ, Boyde A, Murata M, Reynolds JJ, and Meikle MC (1994). Inhibition of bone resorption by selective inactivators of cysteine proteinases. J Cell Biochem 56, 118-130.
44. Goto T, Kiyoshima T, Moroi R, Tsukuba T, Nishimura Y, Himeno M, Yamamoto K, and Tanaka T (1994). Localization of cathepsins B, D, and L in the rat osteoclast by immuno-light and -electron microscopy. Histochemistry 101, 33-40.
45. Schutze N, Oursler MJ, Nolan J, Riggs BL, and Spelsberg TC (1995). Zeolite A inhibits osteoclast-mediated bone resorption in vitro. J Cell Biochem 58, 39-46.
46. Everts V, Korper W, Jansen DC, Steinfort J, Lammerse I, Heera S, Docherty AJ, and Beertsen W (1999). Functional heterogeneity of osteoclasts: matrix metalloproteinases participate in osteoclastic resorption of calvarial bone but not in resorption of long bone. FASEB J 13, 1219-1230.
47. Heidtmann HH, Salge U, Abrahamson M, Bencina M, Kastelic L, Kopitar-Jerala N, Turk V, and Lah TT (1997). Cathepsin B and cysteine proteinase inhibitors in human lung cancer cell lines. Clin Exp Metastasis 15, 368-381.
48. Burnett D, Abrahamson M, Devalia JL, Sapsford RJ, Davies RJ, and Buttle DJ (1995). Synthesis and secretion of procathepsin B and cystatin C by human bronchial epithelial cells in vitro: modulation of cathepsin B activity by neutrophil elastase. Arch Biochem Biophys 317, 305-310.
49. Mai J, Sameni M, Mikkelsen T, and Sloane BF (2002). Degradation of extracellular matrix protein tenascin C by cathepsin B: an interaction involved in progression of gliomas. Biol Chem 383, 1407-1413.
50. Scott LJ, Clarke NW, George NJ, Shanks JH, Testa NG, and Lang SH (2001). Interactions of human prostatic epithelial cells with bone marrow endothelium: binding and invasion. Br J Cancer 84, 1417-1423.
51. Lehr JE and Pienta KJ (1998). Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line. J Natl Cancer Inst 90, 118-123.
52. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, and Chen B (2002). A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94, 1458-1468.
53. Garnero P, Buchs N, Zekri J, Rizzoli R, Coleman RE, and Delmas PD (2000). Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer 82, 858-864.
54. Berruti A, Dogliotti L, Bitossi R, Fasolis G, Gorzegno G, Bellina M, Torta M, Porpiglia F, Fontana D, and Angeli A (2000). Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. J Urol 164, 1248-1253.
55. Akimoto S, Furuya Y, Akakura K, and Ito H (1998). Comparison of markers of bone formation and resorption in prostate cancer patients to predict bone metastasis. Endocr J 45, 97-104.
56. Revilla M, Arribas I, Sanchez-Chapado M, Villa LF, Bethencourt F, and Rico H (1998). Total and regional bone mass and biochemical markers of bone remodeling in metastatic prostate cancer. Prostate 35, 243-247.
57. Nemeth JA, Yousif R, Herzog M, Che M, Upadhyay J, Shekarriz B, Bhagat S, Mullins C, Fridman R, and Cher ML (2002). Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J Natl Cancer Inst 94, 17-25.
58. Inui T, Ishibashi O, Origane Y, Fujimori K, Kokubo T, and Nakajima M (1999). Matrix metalloproteinases and lysosomal cysteine proteases in osteoclasts contribute to bone resorption through distinct modes of action. Biochem Biophys Res Commun 258, 173-178.
59. Delaisse JM, Andersen TL, Engsig MT, Henriksen K, Troen T, and Blavier L (2003). Matrix metalloproteinases (MMP) and cathepsin K contribute differently to osteoclastic activities. Microsc Res Technol 61, 504-513.
60. Keller ET (2002). The role of osteoclastic activity in prostate cancer skeletal metastases. Drugs Today (Barcelona) 38, 91-102.
61. Tezuka K, Tezuka Y, Maejima A, Sato T, Nemoto K, Kamioka H, Hakeda Y, and Kumegawa M (1994). Molecular cloning of a possible cysteine proteinase predominantly expressed in osteoclasts. J Biol Chem 269, 1106-1109.
62. Bromme D, Okamoto K, Wang BB, and Biroc S (1996). Human cathepsin O2, a matrix protein-degrading cysteine protease expressed in osteoclasts. Functional expression of human cathepsin 02 in Spodoptera frugiperda and characterization of the enzyme. J Biol Chem 271, 2126-2132.
63. Bossard MJ, Tomaszek TA, Thompson SK, Amegadzie BY, Manning CR, Jones C, Kurdyla JT, McNulty DE, Drake FH, Gowen M, and Levy MA (1996). Proteolytic activity of human osteoclast cathepsin K. Expression, purification, activation, and substrate identification. J Biol Chem 271, 12517-12524.
64. Gelb BD, Shi GP, Chapman HA, and Desnick RJ (1996). Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 273, 1236-1238.
65. Inui T, Ishibashi O, Inaoka T, Origane Y, Kumegawa M, Kokubo T, and Yamamura T (1997). Cathepsin K antisense oligodeoxynucleotide inhibits osteoclastic bone resorption. J Biol Chem 272, 8109-8112.
66. Hashimoto Y, Kakegawa H, Narita Y, Hachiya Y, Hayakawa T, Kos J, Turk V, and Katunuma N (2001). Significance of cathepsin B accumulation in synovial fluid of rheumatoid arthritis. Biochem Biophys Res Commun 283, 334-339.
67. Hart CA, Scott LJ, Bagley S, Bryden AA, Clarke NW, and Lang SH (2002). Role of proteolytic enzymes in human prostate bone metastasis formation: in vivo and in vitro studies. Br J Cancer 86, 1136-1142.
68. Brubaker KD, Vessella RL, True LD, Thomas R, and Corey E (2003). Cathepsin K mRNA and protein expression in prostate cancer progression. J Bone Miner Res 18, 222-230.
69. Khan KM and Falcone DJ (1997). Role of laminin in matrix induction of macrophage urokinase-type plasminogen activator and 92-kDa metalloproteinase expression. J Biol Chem 272, 8270-8275.
70. Bafetti LM, Young TN, Itoh Y, and Stack MS (1998). Intact vitronectin induces matrix metalloproteinase-2 and tissue inhibitor of metalloproteinases-2 expression and enhanced cellular invasion by melanoma cells. J Biol Chem 273, 143-149.
71. Hornebeck W, Emonard H, Monboisse JC, and Bellon G (2002). Matrix-directed regulation of pericellular proteolysis and tumor progression. Semin Cancer Biol 12, 231-241.
72. Sappino AP, Busso N, Belin D, and Vassalli JD (1987). Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinomas. Cancer Res 47, 4043-4046.
73. Suzumiya J, Hasui Y, Kohga S, Sumiyoshi A, Hashida S, and Ishikawa E (1988). Comparative study of plasminogen activator antigens in colonic carcinomas and adenomas. Int J Cancer 42, 627-632.
74. Kirchheimer JC, Pfluger H, Ritsch LP, Hienert G, and Binder BR (1985). Plasminogen activator activity in bone metastases of prostatic carcinomas as compared to primary tumors. Invasion Metastasis5, 344-355.
75. Sheng S, Pemberton PA, and Sager R (1994). Production, purification, and characterization of recombinant maspin proteins. J Biol Chem 269, 30988-30993.
76. Cher ML, Biliran HR Jr, Bhagat S, Meng Y, Che M, Lockett J, Abrams J, Fridman R, Zachareas M, and Sheng S (2003). Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis. Proc Natl Acad Sci USA 100, 7847-7852.
77. Everts V, Delaisse J, Korper W, Niehof A, Vaes G, and Beertsen W (1992). Degradation of collagen in bone-resorbing compartment underlying the osteoclasts involves both cysteine-proteinases and matrix metalloproteinases. J Cell Physiol 150, 221-231.
78. Tumber A, Papaioannou S, Breckon J, Meikle MC, Reynolds JJ, and Hill PA (2003). The effects of serine proteinase inhibitors on bone resorption in vitro. J Endocrinol 178, 437-447.
79. Eaton CL and Coleman RE (2003). Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment. Cancer Treat Rev 29, 189-198.
80. Teicher BA, Kakeji Y, Ara G, Herbst RS, and Northey D (1997). Prostate carcinoma response to cytotoxic therapy: in vivo resistance. In Vivo 11, 453-461.
81. Heldin CH, Miyazono K, and ten Dijke P (1997). TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 390, 465-471.
82. Lindemann RK, Ballschmieter P, Nordheim A, and Dittmer J (2001). Transforming growth factor beta regulates parathyroid hormone-related protein expression in MDA-MB-231 breast cancer cells through a novel Smad/Ets synergism. J Biol Chem 276, 46661-46670.
83. Van S, Berquin IM, Troen BR, and Sloane BF (2000). Transcription of human cathepsin B is mediated by Sp1 and Ets family factors in glioma. DNA Cell Biol 19, 79-91.
84. Delannoy-Courdent A, Mattot V, Fafeur V, Fauquette W, Rollet I, Calmels T, Vercamer C, Boilly B, Vandenbunder B, and Desbiens X (1998). The expression of an Ets1 transcription factor lacking its activation domain decreases uPA proteolytic activity and cell motility, and impairs normal tubulogenesis and cancerous scattering in mammary epithelial cells. J Cell Sci 111, 1521-1534.
85. Farina AR, Coppa A, Tiberio A, Tacconelli A, Turco A, Colletta G, Gulino A, and Mackay AR (1998). Transforming growth factor-beta1 enhances the invasiveness of human MDA-MB-231 breast cancer cells by up-regulating urokinase activity. Int J Cancer 75, 721-730.
86. Cataisson C, Gordon J, Roussiere M, Abdalkhani A, Lindemann R, Dittmer J, Foley J, and Bouizar Z (2003). Ets-1 activates parathyroid hormone-related protein gene expression in tumorigenic breast epithelial cells. Mol Cell Endocrinol 204, 155-168.
87. Naito S, Shimizu S, Matsuu M, Nakashima M, Nakayama T, Yamashita S, and Sekine I (2002). Ets-1 upregulates matrix metalloproteinase-1 expression through extracellular matrix adhesion in vascular endothelial cells. Biochem Biophys Res Commun 291, 130-138.
88. Thomas GJ, Lewis MP, Hart IR, Marshall JF, and Speight PM (2001). AlphaVbeta6 integrin promotes invasion of squamous carcinoma cells through up-regulation of matrix metalloproteinase-9. Int J Cancer 92, 641-650.
89. Festuccia C, Angelucci A, Gravina G, Eleuterio E, Vicentini C, and Bologna M (2002). Bombesin-dependent pro-MMP-9 activation in prostatic cancer cells requires beta1 integrin engagement. Exp Cell Res 280, 1-11.
90. Dalvi N, Thomas GJ, Marshall JF, Morgan M, Bass R, Ellis V, Speight PM, and Whawell SA (2004). Modulation of the urokinase-type plasminogen activator receptor by the beta6 integrin subunit. Biochem Biophys Res Commun 317, 92-99.
91. Yebra M, Goretzki L, Pfeifer M, and Mueller BM (1999). Urokinase-type plasminogen activator binding to its receptor stimulates tumor cell migration by enhancing integrin-mediated signal transduction. Exp Cell Res 250, 231-240.
92. Kostenuik PJ, Singh G, and Orr FW (1997). Transforming growth factor beta upregulates the integrin-mediated adhesion of human prostatic carcinoma cells to type I collagen. Clin Exp Metastasis 15, 41-52.
93. Haywood-Reid PL, Zipf DR, and Springer WR (1997). Quantification of integrin subunits on human prostatic cell lines-comparison of nontumorigenic and tumorigenic lines. Prostate 31, 1-8.
94. Witkowski CM, Rabinovitz I, Nagle RB, Affinito KS, and Cress AE (1993). Characterization of integrin subunits, cellular adhesion and tumorigenicity of four human prostate cell lines. J Cancer Res Clin Oncol 119, 637-644.
95. Cooper CR, Chay CH, and Pienta KJ (2002). The role of alpha(v) beta(3) in prostate cancer progression. Neoplasia 4, 191-194.
96. Hullinger TG, McCauley LK, DeJoode ML, and Somerman MJ (1998). Effect of bone proteins on human prostate cancer cell lines in vitro. Prostate 36, 14-22.
97. Nemeth JA, Cher ML, Zhou Z, Mullins C, Bhagat S, and Trikha M (2003). Inhibition of alpha(v)beta3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases. Clin Exp Metastasis 20, 413-420.
98. Rozhin J, Sameni M, Ziegler G, and Sloane BF (1994). Pericellular pH affects distribution and secretion of cathepsin B in malignant cells. Cancer Res 54, 6517-6525.
99. Tooze J, Hollinshead M, Hensel G, Kern HF, and Hoflack B (1991). Regulated secretion of mature cathepsin B from rat exocrine pancreatic cells. Eur J Cell Biol 56, 187-200.
100. Wittrant Y, Couillaud S, Theoleyre S, Dunstan C, Heymann D, and Redini F (2002). Osteoprotegerin differentially regulates protease expression in osteoclast cultures. Biochem Biophys Res Commun 293, 38-44.